ArticleDiscover oncology2025
CCR7 in esophageal squamous cell carcinoma: an identification from single-cell and bulk transcriptome sequencing.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConsidering the involvement of CC-chemokine receptor type 7 (CCR7) in diverse tumors, the purpose of our current study is to reveal the specific mechanisms of CCR7 in esophageal squamous cell carcinoma (ESCC).
methodsWe processed single-cell RNA sequencing data based on the Gene Expression Omnibus (GEO) database and utilizing Seurat software, and performed filtering and annotation to obtain different cell types. Genes related to gene ontology biological process and Hallmark were collected, and the enrichment of genes of interested in both single cell and TCGA-ESCA was quantified. Besides, genes related to CCR7 and KRAS signaling up were uploaded to construct the protein-protein interaction network. A series of cellular assays were incorporated to test the effects of CCR7 in ESCC cells.
results28,281 cells were categorized into 4 non-immune cell classes (epithelial cells, smooth muscle cells, fibroblasts, endothelial cells) and 6 immune cell classes (mast cells, plasma B cells, B cells, neutrophils, macrophages, NK/T cells). CCR7 evidently expressed higher in epithelial cells of ESCA and was positively correlated with KRAS signaling up, inflammatory response and TNFA signaling via NFKB, with the most significant correlation witnessed between CCR7 and KRAS signaling up. Meanwhile, the positive correlation between KRAS signaling up and positive regulation of epithelial cell migration was observed. 12 common genes were related to both KRAS signaling up and positive regulation of epithelial cell migration, 3 of which (SOX9, FLT4 and HDAC9) were higher-expressed in M1 group of TCGA-ESCA. Besides, CCR7 as well as its ligands CCL19 and CCL21 was shown to express higher in ESCC cells, where increased level of immune response-related cytokines was seen. CCR7 knockdown diminished migration and proliferation as well as Macrophage M2 polarization.
conclusionCCR7 was highly-expressed in ESCC and positively correlated with KRAS signaling up, which may contribute to the migration of ESCC cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.